WO2001021217A3 - Method of treating cells of the prostate prophylactically or therapeutically - Google Patents

Method of treating cells of the prostate prophylactically or therapeutically Download PDF

Info

Publication number
WO2001021217A3
WO2001021217A3 PCT/US2000/026101 US0026101W WO0121217A3 WO 2001021217 A3 WO2001021217 A3 WO 2001021217A3 US 0026101 W US0026101 W US 0026101W WO 0121217 A3 WO0121217 A3 WO 0121217A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostate
mammal
prophylactically
therapeutically
prophylactic
Prior art date
Application number
PCT/US2000/026101
Other languages
French (fr)
Other versions
WO2001021217A2 (en
Inventor
Joseph T Bruder
C Richter King
Wayne M Kirkman
Imre Kovesdi
Thomas J Wickham
Ping Chen
Stephen C Ransom
Original Assignee
Genvec Inc
Joseph T Bruder
C Richter King
Wayne M Kirkman
Imre Kovesdi
Thomas J Wickham
Ping Chen
Stephen C Ransom
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec Inc, Joseph T Bruder, C Richter King, Wayne M Kirkman, Imre Kovesdi, Thomas J Wickham, Ping Chen, Stephen C Ransom filed Critical Genvec Inc
Priority to AU10709/01A priority Critical patent/AU1070901A/en
Publication of WO2001021217A2 publication Critical patent/WO2001021217A2/en
Publication of WO2001021217A3 publication Critical patent/WO2001021217A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides methods of treating a mammal, such as a mammal suffering from benign prostate hyperplasia, prophylactically or therapeutically. The methods comprise administering a prophylactic or therapeutic nucleic acid operably linked to a promoter to a mammal in need of prophylactic or therapeutic treament of its prostate via transurethral injection, the use of a prostate-specific promoter and/or the use of a targeting moiety that preferentially binds to a prostate cell, instead of a non-prostate cell, whereupon the prophylactic or therapeutic nucleic acid is expressed in cells of the prostate of the mammal, thereby prophylactically or therapeutically treating the mammal.
PCT/US2000/026101 1999-09-23 2000-09-22 Method of treating cells of the prostate prophylactically or therapeutically WO2001021217A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU10709/01A AU1070901A (en) 1999-09-23 2000-09-22 Method of treating cells of the prostate prophylactically or therapeutically

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US15574299P 1999-09-23 1999-09-23
US60/155,742 1999-09-23
US16531899P 1999-11-12 1999-11-12
US60/165,318 1999-11-12
US18057300P 2000-02-04 2000-02-04
US60/180,573 2000-02-04
US20061800P 2000-04-28 2000-04-28
US60/200,618 2000-04-28

Publications (2)

Publication Number Publication Date
WO2001021217A2 WO2001021217A2 (en) 2001-03-29
WO2001021217A3 true WO2001021217A3 (en) 2001-08-09

Family

ID=27496208

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/026101 WO2001021217A2 (en) 1999-09-23 2000-09-22 Method of treating cells of the prostate prophylactically or therapeutically

Country Status (2)

Country Link
AU (1) AU1070901A (en)
WO (1) WO2001021217A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005517394A (en) 2001-12-12 2005-06-16 エフ エイチ フォールディング アンド カンパニー リミテッド Composition for virus preservation
EP2971008B1 (en) 2013-03-14 2018-07-25 Salk Institute for Biological Studies Oncolytic adenovirus compositions
KR101683964B1 (en) * 2014-05-29 2016-12-09 연세대학교 산학협력단 An expression vector comprising nucleic acid downregulating Daxx, TRAIL gene and nucleic acid downregulating Bcl-xL
KR102471633B1 (en) 2016-02-23 2022-11-25 솔크 인스티튜트 포 바이올로지칼 스터디즈 Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
EP3390428B1 (en) 2016-02-23 2019-09-25 Salk Institute for Biological Studies High throughput assay for measuring adenovirus replication kinetics
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031611A2 (en) * 1996-03-01 1997-09-04 Chiron Corporation Treatment of begnin prostatic hyperplasia
WO1998052963A1 (en) * 1997-05-20 1998-11-26 Thomas Jefferson University Fadd-like anti-apoptotic molecules, methods of using the same, and compositions for and methods of making the same
WO1999050425A2 (en) * 1998-03-30 1999-10-07 Baylor College Of Medicine Regulated apoptosis using chemically induced dimerization of apoptosis factors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031611A2 (en) * 1996-03-01 1997-09-04 Chiron Corporation Treatment of begnin prostatic hyperplasia
WO1998052963A1 (en) * 1997-05-20 1998-11-26 Thomas Jefferson University Fadd-like anti-apoptotic molecules, methods of using the same, and compositions for and methods of making the same
WO1999050425A2 (en) * 1998-03-30 1999-10-07 Baylor College Of Medicine Regulated apoptosis using chemically induced dimerization of apoptosis factors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LU YI ET AL: "Delivery of adenoviral vectors to the prostate for gene therapy.", CANCER GENE THERAPY, vol. 6, no. 1, January 1999 (1999-01-01), pages 64 - 72, XP000983967, ISSN: 0929-1903 *
SONG-CHU KO ET AL.: "Molecular therapy with recombinat p53 Adenovirus in an androgen-Independent, Metastatic Human Prostate Cancer Model", HUMAN GENE THERAPY, vol. 7, 1996, pages 1683 - 1691, XP000983941 *
THOMPSON TIMOTHY C.: "In Situ Gene Therapy for Prostate cancer", ONCOLOGY RESEARCH, vol. 11, 1999, pages 1 - 8, XP000983942 *
WICKHAM T J ET AL: "Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins", JOURNAL OF VIROLOGY,US,THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 71, no. 11, November 1997 (1997-11-01), pages 8221 - 8229, XP002121964, ISSN: 0022-538X *

Also Published As

Publication number Publication date
WO2001021217A2 (en) 2001-03-29
AU1070901A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
WO2000066175A3 (en) Conjugates as therapies for cancer and prostate diseases
MXPA02001667A (en) Neurotherapeutic composition and method.
WO2001072962A3 (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2003057179A3 (en) Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
WO2001032926A3 (en) Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
WO2003005889A3 (en) Surgical kit for treating prostate tissue
WO2001023405A3 (en) Therapeutic treatment of androgen receptor driven conditions
TR199901604T2 (en) Quinoline and quinazoline compounds useful in treatment.
WO2003018611A3 (en) Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
EP0696456A3 (en) Combination of necrosis inducing substances with substances which are activated by necrosis for the selective treatment of tumours and or inflammatory diseases
WO1998018493A3 (en) Conjugates useful in the treatment of prostate cancer
WO2001017479A3 (en) Methods and compositions for preventing and treating prostate disorders
WO2001021217A3 (en) Method of treating cells of the prostate prophylactically or therapeutically
WO2002043773A3 (en) Tissue specific prodrugs
WO2002026245A3 (en) Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
EP0817645A4 (en) Method for treatment of benign prostatic hypertrophy
DK1007095T3 (en) Chimeric toxins including GnRH for targeted therapy
WO2001030804A3 (en) Salt form of a conjugate useful in the treatment of prostate cancer
AU2193797A (en) Delivery of therapeutic agents to the prostate
WO2001090159A3 (en) Compositions and methods for delivery of a molecule into a cell
EA200401100A1 (en) 1α-FTOR-25-HYDROXY-16,23E-DIEN-26,27-BISHOMO-20-EPICHOLOCALTI-SPHEROL AND ITS APPLICATION FOR TREATMENT
WO2002048112A3 (en) 7-heterocyclyl quinoline and thieno[2,3-b]pyridine derivatives useful as antagonists of gonadotropin releasing hormone
WO2000020589A3 (en) PTANs: TESTIS SPECIFIC PROTEINS EXPRESSED IN PROSTATE CANCER
WO2001032685A3 (en) Gene expression directed by a super-psa promoter

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP